Drugs in development for herpes simplex and varicella zoster virus.
The alpha-herpesviruses varicella zoster virus (VZV) and herpes simplex virus (HSV) share common features including lifelong persistence in sensory ganglia and the risk of recurrences. For both HSV and VZV, standard-of-care (SoC) is based on nucleoside analogs (NAs), which require specific activation in infected cells. These existing drugs exhibit substantial limitations, warranting the development of new and more effective drugs.
AiCuris Anti-infective Cures GmbH, Wuppertal, Germany.
A
A
Birkmann
AiCuris Anti-infective Cures GmbH, Wuppertal, Germany.
H
H
Zimmermann
D000998:Antiviral Agents / Q000145:classification / Q000494:pharmacology; D004265:DNA Helicases / Q000037:antagonists & inhibitors; D019915:DNA Primase / Q000037:antagonists & inhibitors; D006561:Herpes Simplex / Q000188:drug therapy* / Q000821:virology; D006562:Herpes Zoster / Q000188:drug therapy* / Q000821:virology; D014645:Herpesvirus 3, Human / Q000187:drug effects / Q000502:physiology; D006801:Humans; D054539:Medication Therapy Management / Q000639:trends; D009705:Nucleosides / Q000494:pharmacology; D018139:Simplexvirus / Q000187:drug effects / Q000502:physiology; D014764:Viral Proteins / Q000037:antagonists & inhibitors; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D009705:Nucleosides; D014764:Viral Proteins; D019915:DNA Primase; C062021:helicase-primase, Human herpesvirus 1; D004265:DNA Helicases